Vermillion (Fremont, California) reported hiring ThinkPanmure, an investment bank, to assist in identifying and evaluating alternatives intended to enhance the potential of the company's proteomic tests (OVA1 and VASCLIR) and pipeline of biomarkers.

"We continuously evaluate our strategic options to identify and develop prospects for maximizing value for all stockholders and look forward to working with ThinkPanmure in this regard," said Gail Page, president/CEO of Vermillion. "While reviewing the various alternatives, we will continue to advance our commercialization strategies, namely building marketplace awareness for our women's health, oncology, and cardiac programs which include the OVA1 and VASCLIR tests."

Vermillion makes diagnostic products for oncology, hematology, cardiology and women's health.